Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
OTCMKTS:ORINY

Orion OYJ Q3 2026 Earnings Results & Report

Orion OYJ logo
$54.20 -0.58 (-1.05%)
As of 09:31 AM Eastern

Orion OYJ reported Q3 2026 earnings on October 28, 2026. The company reported EPS of $0.68.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Orion OYJ EPS Results

Actual EPS
$0.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Orion OYJ Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Orion OYJ Q3 2026 Earnings FAQ

Orion OYJ (OTCMKTS:ORINY) reported earnings of $0.68 per share for Q3 2026. The report was announced on Wednesday, October 28, 2026.

Orion OYJ Earnings Headlines

Orion Oyj
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
See More Orion OYJ Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orion OYJ? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orion OYJ and other key companies, straight to your email.

About Orion OYJ

Orion OYJ (OTCMKTS:ORINY), also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo. The company serves customers in Finland and international markets through its own operations, commercial partners and licensing arrangements, with its products available in numerous countries.

View Orion OYJ Profile